|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT00952991 |
|
Date of registration:
|
04/08/2009 |
|
Primary sponsor: |
|
|
Public title:
|
The Effects of LAF237 on Gastric Function in Type 2 Diabetes
|
|
Scientific title:
|
A Double Blind, Cross Over, Placebo Controlled, Multiple-dose Study to Evaluate the Effects of LAF237 on Gastric Emptying, Gastric Volume and Satiety in Patients With Type 2 Diabetes. |
|
Date of first enrolment:
|
May 2005 |
|
Target sample size:
|
18 |
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT00952991 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment
|
|
|
Countries of recruitment
|
|
United States
| | | | | | | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Type 2 diabetes without microvascular or macrovascular complications treated with
diet or up to 2 oral agents
Age minimum:
35 Years
Age maximum:
70 Years
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Diabetes Mellitus, Non-Insulin-Dependent
|
|
Intervention(s)
|
|
Drug: LAF237 = vildagliptin
|
|
Primary Outcome(s)
|
|
Gastric accommodation
|
|
Gastric Emptying
|
|
Gastrointestinal Symptoms
|
|
Satiety
|
|
Secondary Outcome(s)
|
|
Endogenous Glucose Production
|
|
Glucagon Secretion
|
|
Glucose Disappearance
|
|
Insulin Secretion
|
|
Meal Appearance Rate
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|